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Acute systemic toxicity studies are carried out in many sectors in
which synthetic chemicals are manufactured or used and are
among the most criticized of all toxicology tests on both scientiﬁc
and ethical grounds. A review of the drivers for acute toxicity
testing within the pharmaceutical industry led to a paradigm shift
whereby in vivo acute toxicity data are no longer routinely required
in advance of human clinical trials. Based on this experience, the
following review was undertaken to identify (1) regulatory and
scientiﬁc drivers for acute toxicity testing in other industrial sectors,
(2) activities aimed at replacing, reducing, or reﬁning the use of
animals, and (3) recommendations for future work in this area.
Key Words: 3Rs; acute toxicity; harmonization; hazard labeling;
limit dose; redundancy; regulatory classiﬁcation; systemic toxicity.
This review has been carried out under the auspices of the
European Partnership for Alternative Approaches to Animal
(EPAA) Testing, an unprecedented collaboration between the
European Commission (EC), European industry trade associ-
ations, and companies from seven industrial sectors. The
partners are committed to pooling knowledge and resources to
accelerate the development, validation, and acceptance of
alternative approaches to further the reduction, reﬁnement, and
replacement (3Rs) of animal use in regulatory testing.
The term ‘‘acute toxicity’’ is used to describe the adverse
effects of a substance that may result from a single exposure or
multiple exposures within a 24-h period. Acute effects may be
local (e.g., skin or eye irritation) and/or systemic in nature. This
review focuses on the latter, with emphasis on regulatory
required high-dose studies carried out via oral, dermal, and
inhalation routes of exposure for the purpose of identifying or
estimating doses that cause lethality. Other types of acute
studies such as nonlethal single-dose studies (e.g., for derivation
of an acute reference dose), acute ecotoxicological studies in
ﬁsh and avian species, testing for marine biotoxins, and safety/
potency testing of vaccines are not explored in this paper.
Acute systemic toxicity studies are rooted in the post-World
War I era concept of the ‘‘LD50,’’ which was deﬁned by Trevan
(1927) as the single dose of a substance that can be expected to
cause death in 50% of the animals in an experimental group.
Initially developed to provide a relative index of toxicity for plant
and biological extracts, LD50-type studies achieved general
acceptance as a basis of comparing and classifying the toxicities
of chemicals (FDA, 1988) and have become a routine testing
requirement in a number of regulatory sectors (Botham, 2004).
AccordingtoEC(2007)animalusestatistics,acutetoxicitystudies
remain the most prevalent class of toxicological test in use today.
Acute lethality studies have been among the most heavily
criticized of all regulatory toxicity tests, both on scientiﬁc and
on ethical grounds (Ekwall et al., 1998; Langley, 2005; Lorke,
1983; Zbinden and Flury-Roversi, 1981). In response to
criticisms, there has been a gradual evolution in study designs
for acute systemic toxicity consistent with the 3Rs principle
(Russell and Burch, 1959), coupled with increasingly sophis-
ticated efforts to move away from animal testing altogether
(Table 1). Notably, reduction and in part reﬁnement methods
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Cooperation and Development (OECD) Test Guidelines for
oral and inhalation routes, although no such approach for
dermal exposure is currently available. And despite efforts over
many years, acute toxicity testing remains a core regulatory
requirement in many sectors.
TABLE 1
Acute Toxicity Testing: 1927 Through the Present
Date Milestone
1927 British pharmacologist John Trevan publishes ﬁrst paper describing the LD50 test
1930s LD50 test becomes gradually accepted for the standardization of toxic plant and biological extracts and other chemicals (FDA, 1988)
1959 Publication of The Principles of Humane Experimental Technique outlining the ‘‘3Rs’’ principle of replacement, reduction, and reﬁnement of animal
use
1973 Swiss toxicologist Zbinden (1973) publishes a review that concludes there is little justiﬁcation for conducting the classical LD50
1981 The OECD adopts Test Guidelines 401–403, the ‘‘classical’’ oral, dermal, and inhalation LD/LC50 tests
1984 The British Toxicology Society (BTS, 1984) concludes that precisely determined LD50 values are rarely justiﬁed and proposes the alternative Fixed
Dose Procedure
1987 OECD 401 is revised to reduce number of animals used, e.g., only one sex required, and in some regions, the limit dose is reduced from 5000 to
2000 mg/kg
1988 US Food and Drug Administration publishes a policy on the LD50 stating ‘‘The scientiﬁc community agrees that the ‘‘classical’’ LD50 test is not
necessary for determining acute toxicity. The agency supports efforts to discontinue conduct of the ‘‘classical’’ LD50 test and to reduce the numbers
of animals used in acute toxicity testing without sacriﬁcing information necessary in the interest of human safety’’ (FDA, 1988)
1992 Adoption of OECD 420: Fixed Dose Procedure, a reduction and reﬁnement alternative to OECD 401, the classical oral LD50 test
1996 Adoption of OECD 423: Acute Toxic Class Method, a second reduction alternative to OECD 401
1998 Adoption of OECD 425: Up-and-Down Procedure, a third alternative to OECD 401
Results of the Multicentre Evaluation of In Vitro Cytotoxicity are released by Ekwall et al. (1998) illustrating a strong concordance between a battery of
in vitro cytotoxicity assays and human lethal blood concentrations for 50 chemicals
1999 OECD member countries agree in principle to delete TG 401
British Home Ofﬁce discontinues issuing licenses for LD50 if a suitable alternative is available (HO, 1999)
2000 ICCVAM/NICEATM (2001b) convene an International Workshop on In Vitro Methods for Assessing Acute Systemic Toxicity to explore the potential
to use nonanimal methods to predict LD50 values
2001 ICCVAM/NICEATM (2001a) publish a Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity
2002 OECD (2002) ofﬁcially deletes TG 401 from its internationally harmonized guidelines
Commencement of the joint ICCVAM/ECVAM international validation study of in vitro cytotoxicity test methods for estimating acute oral systemic
toxicity
2003 ECVAM holds a Workshop on Strategies to Replace In Vivo Acute Systemic Toxicity Testing (Gennari et al., 2004)
European pharmaceutical company/NC3Rs working group formed
2005 Pharmaceutical companies and NC3Rs organize a regulatory workshop to discuss the requirement for acute toxicity tests in the development of new
human medicines (Chapman and Robinson, 2007)
Launch of the 15 million Euro, pan-European ACuteTox integrated project (‘‘ACuteTox.org’’)
Pesticide regulators propose a new nonlethal study design for the derivation of an ‘‘acute reference dose’’ (Solecki et al., 2005)
2006 Publication of the peer review report of the joint ICCVAM/ECVAM international validation study of in vitro cytotoxicity test methods for estimating
acute oral systemic toxicity (ICCVAM/NICEATM, 2006)
NC3Rs organizes a regulatory workshop to discuss drivers for acute toxicity testing within the pharmaceutical sector (Chapman and Robinson, 2007)
2007 US National Research Council report ‘‘Toxicity Testing in the 21st Century’’ calls for a transition toward a mechanistic, and predominantly animal-free,
paradigm in toxicology, which offers a possible path forward for replacing in vivo systemic toxicity testing (NRC, 2007)
US Environmental Protection Agency ‘‘ToxCast’’ program launched to build computational models to forecast human toxicity (EPA, 2008b, 2009)
2008 Publication of a review of the scientiﬁc drives for acute toxicity testing within the pharmaceutical industry (Robinson et al., 2008)
EPAA establishes a cross-sector task force on acute toxicity
ECVAM funds a follow-up validation study of the 3T3 Neutral Red Uptake cytotoxicity assay (ICCVAM/NICEATM, 2006) to evaluate the predictive
capacity of the assay to identify substances with acute oral LD50 > 2000 mg/kg (Kinsner-Ovaskainen et al., 2009)
NC3Rs establishes an expert working group to develop the scientiﬁc evidence needed to support regulatory acceptance of the Fixed Concentration
Procedure for acute inhalation toxicity testing
ICCVAM (2008) issues test method recommendations to U.S. agencies regarding use of two in vitro methods for estimating starting doses for acute oral
toxicity studies
U.S. federal agencies announce ‘‘Tox21’’ collaboration on high throughput screening, toxicity pathway proﬁling, and biological interpretation of
ﬁndings (HHS & EPA, 2008)
2009 Adoption of ICH M3(R2) test guideline, including a reduction of the standard limit dose to 1000 mg/kg (ICH, 2009)
Adoption of OECD 436: Acute Toxic Class Method, a reduction alternative to OECD 403, the classical inhalation LC50 test, together with a revision to
403 (OECD, 2009c)
OECD publishes a Draft Guidance Document on Using Cytotoxicity Tests to Estimate Starting Doses for Acute Oral Systemic Toxicity Tests (OECD,
2009a)
ACUTE TOXICITY DRIVERS AND ALTERNATIVES 383In 2003, a working group comprised 18 international
pharmaceutical companies and contract testing laboratories,
together with the U.K. National Centre for the Replacement,
Reﬁnement, and Reduction of Animals in Research (NC3Rs),
was established to evaluate the utility of acute systemic toxicity
studies in the development of new medicines. The expert group
determined that ‘‘the information obtained from acute toxicity
studies is of little or no value in the pharmaceutical
development process,’’ a conclusion subsequently considered
and endorsed by pharmaceutical regulators and scientists via
the International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human
Use (ICH) process (ICH, 2009; Robinson et al., 2008). In light
of these ﬁndings, and in view of the requirement of acute
toxicity testing across multiple industry sectors, the EPAA
established a task force to examine scientiﬁc and regulatory
drivers for such testing and to promote the use of 3Rs
approaches that the task force considers are currently available.
This publication is one of several products of that effort.
CURRENT PRACTICE
Survey of EPAA Member Companies
A questionnaire designed to gather information regarding
current practices in the conduct of acute toxicity studies and
companies’ experiences in this area was sent to all EPAA
members except those in the pharmaceutical sector, which has
already participated in such an exercise (Robinson et al., 2008).
The EPAA survey questions covered the scientiﬁc and
regulatory objectives of the studies, routes of administration,
preferred test guideline, parameters examined, dose limit, and
regulatory experience (a link to the EPAA questionnaire is
included under ‘‘Supplementary data’’). Seventeen companies
responded, and the number of companies responding per sector
is outlined as follows: agrochemicals (four companies), animal
health (two companies), consumer products/cosmetics (nine
companies), industrial chemicals (four companies), and
together with two contract research organizations that conduct
studies to support the various sectors. The total number of
responding companies appears greater than 17 because some
companies represent more than one sector. The aggregated
responses are not detailed in this publication because the
number of companies responding within each sector was
relatively small. The limited nature of the survey means that
generalized qualitative responses rather than quantitative data
are used to support the points made in relevant sections of this
publication. Reference to the earlier pharmaceutical company
survey is also made when relevant.
Number of Animals and End Points Measured in Guideline
Studies
Table 2 compares current and proposed protocols for acute
toxicity studies and identiﬁes study designs used to determine
LD50 point estimates versus range estimates, as well as how
many animals are typically used under each protocol. A full
statistical breakdown of animal use across industry sectors and
in various classes of acute toxicity studies is available
elsewhere (EC, 2007).
Contemporary test guidelines offer greater ﬂexibility for
generating data ﬁt for purpose, potentially using fewer animals
than the older guidelines, such as the now-deleted OECD Test
Guideline 401 (OECD, 2009c). It is also possible to use clinical
signs such as ‘‘evident toxicity’’ rather than death as an end
point for classiﬁcation, e.g., in the U.K.-pioneered Fixed Dose
Procedure (OECD 420).
Choice of test guideline is driven in large part by national and
sector-speciﬁc regulatory requirements but can also be inﬂu-
enced by what the LC50 or LD50 might reasonably be expected
to be. For example, if there is reason to expect that the acute
toxicity will be greater than the limit dose for classiﬁcation,
OECD 420 would be a suitable choice in using the fewest
animals to achieve this end. If this is not absolutely certain, the
German-developed Acute Toxic Class Method (OECD 423)
may ultimately use the fewest animals. If on the other hand
a point estimate of the oral LD50 is required, the U.S.-developed
Up-And-Down Procedure (OECD 425) would be required.
According to EPAA’s survey of members, many European
companies and contract research organizations default to OECD
423 unless a speciﬁc regulatory authority requires a more
humane method or a point estimate of the LD50.
Foracutedermaltoxicity,theonlyguidelinecurrentlyavailable
is the classic dermal LD50 study (OECD 402). An OECD dermal
ﬁxed dose guideline was proposed in 2004 but has since been
withdrawn. Acute dermal studies are normally performed after
oralorinhalationtesting,andasdiscussedlaterinthispublication,
dermal toxicity is rarely greater than what is observed in oral or
inhalation studies. Thus, a limit test is normally sufﬁcient.
For acute inhalation toxicity, a revised version of the classic
mammalian LC50 study (OECD 403) has recently been
adopted, together with a new Acute Toxic Class guideline
(OECD 436) as an animal reduction measure. An inhalation
Fixed Concentration Procedure has also been proposed, and
work to develop the scientiﬁc evidence needed to support the
adoption of this method is currently ongoing (see Table 1).
SCIENTIFIC AND REGULATORY DRIVERS FOR ACUTE
TOXICITY STUDIES
Regulatory Drivers in Different Sectors and Regions
By sector. Most countries examined have enacted legisla-
tion and regulations governing the testing and marketing of
agricultural and industrial chemicals, biocides, cosmetics, food
additives, medicinal products, and other substances for the
protection of human health and the environment. A multisector
and multiregional overview of regulatory data require-
ments for acute systemic toxicity is presented in Table 3.
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Comparison of OECD Guidelines for Acute Systemic Toxicity (adapted from Botham, 2004)
Route Oral
a Dermal
b Inhalation
c
OECD test
guideline (year
of adoption)
401 LD50 (1981;
deleted 2001)
420 ﬁxed dose
(1992)
423 acute toxic
class (1996)
425 up and down
(1998)
402 LD50 (1981) Draft 434 ﬁxed
dose (on hold)
403 LC50 (1981) 403 LC50 (revised
2009)
436 acute toxic
class (2009)
Sighting study
required?
Yes 1 animal per [ ] No No Yes Yes   3 # and   3 $
(or   3o f
susceptible sex)
p er[].Atleast3#
and 3 $ p e r[]t o
testsexdifferences
if unknown
  3 # and   3 $
per [ ]
No
Dose levels At least 3, spaced
appropriately to
produce test
groups with
a range of toxic
effects and
mortality rates.
The data should
be sufﬁcient to
produce a dose-
response curve
and, where
possible, permit
an acceptable
determination of
the LD50. May
also be used as
a limit test. At
least 5 rodents of
the same sex per
dose level
Fixed doses of 5,
50, 300, and
2000 (5000)
mg/kg; 5
animals/dose
level
Fixed doses of 5,
50, 300, and
2000 (5000)
mg/kg; 3
animals/dose
level
Starting dose at
best estimate of
LD50 (or 175
mg/kg) and using
dose progression
factor of 3.2,
single animals
dosed until one
of three stopping
criteria met
At least 3, spaced
appropriately to
produce test
groups with
a range of toxic
effects (including
death). Data
should be
sufﬁcient to
produce a dose-
response curve
and, where
possible, permit
an acceptable
determination of
the LD50. May
also be used as
a limit test. At
least 5 rodents of
the same sex per
dose level
Fixed doses of 5,
50, 300, and
2000 (5000)
mg/kg; 5
animals/dose
level
At least 3, spaced
appropriately to
produce test
groups with
a range of toxic
effects and
mortality rates.
Data should be
sufﬁcient to
produce a dose-
response curve
and, where
possible, permit
an acceptable
determination of
the LC50. May
also be used as
a limit dose test.
At least 10
rodents (at least 5
of each sex) per
dose level
At least 3, spaced to
produce a range of
toxic effects
(including death).
Thedatashouldbe
sufﬁcient to
produce a dose-
response curve
and permit an
acceptable
determination of
theLC50.—or––as
aC3 Tp r o t o c o l
for deriving
AEGL, ERPG, or
AETL values for
emergency
responseplanning,
or land use
planning. May
also be used as
a limit dose test.
Al i m i tv e r s i o no f
theC3Tprotocol
m a ya l s ob e
performed. At
least 5 rodents of
the same sex per
dose level should
be used in the
traditional
protocol. One
animal/sex/
interval under the
C 3 Tp r o t o c o l
Fixed doses during
and exposure
period of 4 h; 3
animals/sex/dose
level or 6
animals of the
more sensitive
sex/dose level
A
C
U
T
E
T
O
X
I
C
I
T
Y
D
R
I
V
E
R
S
A
N
D
A
L
T
E
R
N
A
T
I
V
E
S
3
8
5TABLE 2—Continued
Route Oral
a Dermal
b Inhalation
c
Average number
of animals
> 20 5 (limit test) to 7 6 (limit test) to 7 5 (limit test) to 9 10 (limit test)
to 30
5 (limit test) to 7 40 If 4 concentrations
tested:
6–9
—In case of 1
animal/sex/(C 3
T) point: both
sexes ¼ 40;
susceptible sex ¼
40
—In case of 2
animals/sex/ (C
3 T) point: both
sexes ¼ 80;
susceptible sex ¼
80
Aim Identify the LD50
and the range of
associated toxic
effects
Identify lowest
ﬁxed dose
causing evident
toxicity
Identify lowest
ﬁxed dose
causing mortality
Calculated LD50 Identify the LD50
and the range of
associated toxic
effects
Identify lowest
ﬁxed dose
causing evident
toxicity
Identify the LC50
and the range of
associated toxic
effects
Identify the LC50
and the range of
associated toxic
effects
Identify the LC50
and the range of
associated toxic
effects
Output Point estimate of
LD50 with
conﬁdence
intervals; signs
of acute toxicity;
target organ(s)
Range estimate of
LD50; signs of
acute toxicity;
target organ(s)
Range estimate of
LD50; signs of
acute toxicity;
target organ(s)
Point estimate of
LD50 with
conﬁdence
intervals; signs
of acute toxicity;
target organ(s)
Point estimate of
LD50 with
conﬁdence
intervals. Signs
of acute toxicity.
Target organ(s)
Range estimate of
LD50; signs of
acute toxicity;
target organ(s)
Point estimate of
LC50 with
conﬁdence
intervals; signs
of acute toxicity;
target organ(s)
Range estimate of
LC50; signs of
acute toxicity;
target organ(s)
Range estimate of
LC50; signs of
acute toxicity;
target organ(s)
Note. #, male; $, female; [ ], concentration; C 3 T, concentration 3 time protocol; AEGL/AETL, acute exposure guideline/threshold level; ERPG, emergency response planning guideline.
aSingle bolus. Young adult rats (‘‘one sex’’). Oral gavage with constant volume or concentration, clinical observations, bodyweight, and mortality over 14 days. Necropsy at termination. It is
recommended that only one sex needs to be tested initially followed by a second group of the other sex tested to investigate sex differences unless data exist to show the ﬁrst sex is the more sensitive.
bYoung adult rats (‘‘one sex’’). Dermal application to 10% of skin surface area (clipped free of hair) for 24 h under a gauze and tape dressing. Clinical observations, bodyweight, and mortality over
14 days. Necropsy at termination. It is recommended that only one sex needs to be tested initially followed by a second group of the other sex tested to investigate sex differences unless data exist to show
the ﬁrst sex is the more sensitive.
cYoung adult rats (‘‘one sex’’). Inhalation exposure for at least 4 h in rat and mice in the current 403 or up to 6 h for rats in the proposed revised 403 (up to 4 h for mice only). Clinical observations,
bodyweight, and mortality over 14 days. Necropsy at termination. It is recommended that only one sex needs to be tested initially followed by a second group of the other sex tested to investigate sex
differences unless data exist to show the ﬁrst sex is the more sensitive. Alternative protocol under proposed revision to 403: C 3 T protocol: young adult rats, exposed to a test article at several
concentration levels and for multiple time durations (1 animal/sex/interval). All testing is performed in a nose-only chamber.
3
8
6
S
E
I
D
L
E
E
T
A
L
.This illustrates the complexity of the regulatory arena across
sectors and countries and the challenges this creates for those
seeking to reduce the numbers of animals used in acute toxicity
studies while generating globally acceptable registration data
packages.
For ‘‘agrochemicals and biocides,’’ acute data for three
routes of administration (oral, dermal, and inhalation) are
generally required for all active substances and in many cases
for formulated products and certain other chemical ingre-
dients as well (EPA, 2007b, 2008a; FAMIC, undated; GC,
2006; MOA, 2001; OJ, 1992, 1998). Requirements for
‘‘industrial chemicals’’ are generally less rigid, with most
countries examined requiring testing by a single route or
possibly two routes for higher tonnage substances (GC, 2005;
MEP, 2004a; OJ, 2007). Some countries currently impose no
speciﬁc data requirement for acute toxicity testing of
industrial chemicals (EPA, 2007a; METI, 2005)o rn ot e s t i n g
below a speciﬁed production volume, e.g., one metric ton in
the European Union (EU) (OJ, 2007). Within the EU, the
only ofﬁcially recognized methods for the determination of
acute oral toxicity of industrial chemicals are OECD TG 420
and OECD 423 (OJ, 2004, 2008), which is a consideration
when determining a test to be used across geographical
regions and regulatory frameworks. The EPAA survey
conﬁrmed implementation of these regulatory requirements
in practice.
For ‘‘cosmetics,’’ acute toxicity testing of both ﬁnished
products and raw ingredients is now prohibited in the EU (OJ,
2003) and not speciﬁcally required in the United States or
Canada, although information on systemic effects may be
obtained using other methods to ensure the legally required
safety of the product. In Japan, for cosmetics consisting of
ingredients already on an approved list, there is no requirement
for additional testing. In contrast, China and certain South
American countries require premarket registration of cosmetic
ﬁnished products, which may entail some level of acute
toxicity testing above and beyond the safety assessment of raw
ingredients (RPA, 2004). Additionally, some of these countries
do not consistently accept foreign data, which may result in
cosmetic products produced by foreign companies being
subject to duplicate testing.
For ‘‘food additives, ﬂavorings, and food-contact materials,’’
a speciﬁc requirement to generate acute systemic toxicity data
could not be found in applicable legislation, regulations, or
guidance in any of the countries surveyed (EC, 2001a, 2001b;
FDA, 2002, 2006; MHLW, 2009).
For the development of new ‘‘human medicines,’’ the
requirement for acute toxicity tests is now largely historic
because the revised text of ICH Test Guideline ‘‘M3 R2’’ was
adopted last year (ICH, 2009). All that remains is for the
regional guidelines in Europe, the United States, and Japan to
be updated to reﬂect the text of the revised ICH M3. Many
pharmaceutical companies have not conducted acute toxicity
studies for new medicines for some time because data
generated from other more reﬁned study types (e.g., in vivo
genetic toxicology studies, safety pharmacology studies, and
dose-range ﬁnding studies), which are already conducted as
part of the development of new medicines, are considered to
provide a better assessment of potential human safety risks in
advance of clinical trials. The same is true regarding the
protection of workers in manufacturing and production plants,
such that most companies are now using data from other
studies to inform Material Safety Data Sheets and other worker
protection measures.
With respect to ‘‘veterinary medical products,’’ acute
toxicity studies are not speciﬁcally required for the demon-
stration of safety either to target animals or to human
consumers (EMEA, 2009; OJ, 1990; VICH, 2008). However,
acute studies may be carried out on a voluntary basis to obtain
information on other aspects of safety for veterinary medical
product (e.g., worker protection), though as above, other
available data could be used for these purposes.
Across all sectors and countries examined, it is generally
accepted that acute toxicity studies may be waived if
a substance is known to be corrosive or if there is a low risk
of human exposure (ECHA, 2008b). Route-speciﬁc waivers
may be granted on the basis of physicochemical properties,
such as volatility, particle size, molecular weight and volume,
and log Kow (ECHA, 2008c). A notable exception is for
agrochemical and biocide active substances in the EU, where
acute toxicity studies must usually be carried out for hazard
classiﬁcation of the active substances regardless of the
expected exposure. For formulations, waivers may be granted
in cases where a scientiﬁcally sound case can be made, e.g.,
when the outcome of the study is highly predictable based on
the properties and concentration of individual ingredients
(EPA, 2001; OJ, 1999). Weight-of-evidence and read-across
approaches might also be used to estimate acute toxicity
(discussed further in the ‘‘Alternative Approaches’’ section
below).
Classiﬁcation and labeling. Classiﬁcation and labeling of
substances and products is relevant to various sectors.
Regulatory authorities across the globe have also developed
frameworks for the classiﬁcation and labeling of chemical
hazards for the protection of workers, consumers, and
the environment. In many cases, the regulatory requirement
for acute toxicity data is for classiﬁcation and labeling
purposes only, a fact conﬁrmed by the EPAA survey, with
the majority of companies identifying classiﬁcation and
labeling as a primary reason for conducting acute toxicity
testing.
When testing is conducted solely to meet classiﬁcation and
labeling requirements, precise LD50/LC50 values are not
necessary because testing to the upper boundary of a hazard
category (i.e., limit dose) is sufﬁcient to establish a regulatory
classiﬁcation. Therefore, there is no scientiﬁc necessity to
establish a dose-response curve for mortality.
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Regulatory Drivers for Acute Toxicity Testing Across Agrochemicals, Biocides, Chemicals, Cosmetics, and Medicinal Products Sectors
Sector Europe United States Japan China
Agrochemicals Regulation (EC) No 1107/2009 (OJ, 2009);
data requirements speciﬁed in Annexes II
and III. The recently revised EU regulation
makes sharing of vertebrate data between
applicants and notiﬁers obligatory (in
a manner similar to REACH) so that
duplicate testing is avoided. At the time of
this writing, data requirements are still
being revised via an independent
comitology process. Annex II requires
acute oral and dermal data for each active
substance, and an inhalation study must be
performed except where exposure via this
route can be ruled out. Annex III
requirements for formulated products
prescribe separate acute oral and dermal
studies; however, classiﬁcation by
calculation should be a viable alternative
for most formulations.
Federal Insecticide, Fungicide, and
Rodenticide Act (USC, 2008b); data
requirements for active substances/
formulations speciﬁed in 40 CFR § 158
(EPA, 2007b); guidance on determining
data needs for other ingredients provided
by EPA (2002). Part 158 prescribes acute
systemic toxicity studies via oral, dermal,
and inhalation routes for the active
substance. Additionally, each ﬁnished
product/formulation is normally also
required to undergo separate acute toxicity
testing via the oral, dermal, and inhalation
routes for labeling purposes, although data
waivers may be granted in cases where
a scientiﬁcally sound argument can be
made (EPA, 2001). Acute systemic
toxicity data are not normally required in
the United States for nonactive ingredients
in a pesticide formulation (EPA, 2002).
Agricultural Chemicals Regulation Law
(MAFF, 1948); Appendix to Data
Requirements for Supporting Registration
of Pesticides (FAMIC, undated). Acute
toxicity data requirements are generally
consistent with those of other countries
listed here, with the proviso that dermal
studies may be waived if a substance is
corrosive, and inhalation studies may be
waived ‘‘when it is determined that there
is no danger that users will be exposed to
the relevant agricultural chemical through
inhalation.’’
Regulation on Pesticide Administration (SC,
2001); Requirements of the Pesticide
Registration Document (MOA, 2001).
Acute toxicity data requirements are
generally consistent with those of the EU
and the United States.
Biocides Directive 98/8/EC (OJ, 1998); data
requirements speciﬁed in Annexes II and
III. At the time of writing, Directive 98/8/
EC is in the process of being replaced by
the Biocidal Products Regulation (EC,
2009). With respect to acute systemic
toxicity of the active ingredient, oral data
are normally required except where
inhalation data area available, and
inhalation and dermal data are required
except where exposure via these routes can
be ruled out. Annex III requirements (for
formulated products) prescribe acute
testing via at least two routes. Article 13 of
the Biocides Directive, however, does
specify mechanisms by which vertebrate
data sharing must occur for existing
actives.
Federal Insecticide, Fungicide, and
Rodenticide Act (USC, 2008b); data
requirements for active substances/
formulations speciﬁed in 40 CFR Part
158W (EPA, 2008a); guidance on
determining data needs for other
ingredients provided by EPA (2002).
Acute toxicity requirements are the same
as for agrochemicals.
Regulated as industrial chemicals Regulated as industrial chemicals
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.TABLE 3—Continued
Sector Europe United States Japan China
Cosmetics Directive 76/768/EEC, as amended (OJ,
2003, 2006); guidance regarding data
needs provided by the Scientiﬁc
Committee on Consumer Safety (SCCP,
2006). At the time of this writing, the
Cosmetics Directive is being recast as an
EU regulation. This process does not alter
existing or future marketing bans on
products containing animal tested
ingredients. Animal testing for acute
systemic toxicity is banned in the EU as of
March 2009, as is the marketing of
cosmetic products containing ingredients
that have been subject to acute testing on
animals after that date.
Federal Food, Drug, and Cosmetic Act
(USC, 2008a). Cosmetics are not subject
to speciﬁc testing requirements or
premarket approval in the United States.
However, the Federal Food, Drug and
Cosmetic Act broadly prohibits the
marketing of adulterated or misbranded
cosmetics, including any product (other
than a hair dye) that ‘‘bears or contains
any poisonous or deleterious substance
which may render it injurious to users
under the conditions of use prescribed in
the labeling thereof, or under conditions of
use as are customary and usual.’’
Companies are encouraged to register their
establishments and ﬁle Cosmetic Product
Ingredient Statements with FDA’s
Voluntary Cosmetic Registration Program
Pharmaceutical Affairs Law; Standards for
Cosmetics (MHLW, 2000). Cosmetics are
not subject to speciﬁc testing
requirements. However, they ‘‘shall not
contain anything that may cause infection
or that otherwise makes the use of the
cosmetics a potential health hazard.’’
Regulations Concerning The Hygiene
Supervision Over Cosmetics (MPH, 1989).
A distinction is made between ‘‘ordinary
cosmetics’’ such as shampoos, deodorants,
and lipstick and ‘‘special use cosmetics’’
such as sunscreens, depilatory creams, and
weight loss products, as well as between
domestic and imported cosmetics (RPA,
2004). Strict premarket requirements are
imposed in China for all imported
cosmetics, with special cosmetics (both
domestic and imported) being subject to
a safety assessment including acute
toxicity testing. China is not a party to the
OECD Council Decision Regarding the
Mutual Acceptance of Data (OECD, 1981)
and by extension does not typically accept
foreign data. As a consequence, cosmetic
products produced by foreign companies
may therefore be subject to duplicate
testing within China (RPA, 2004).
Chemicals Regulation (EC) No 1907/2006 (REACH)
(OJ, 2007); data requirements are speciﬁed
in Annexes VII–XI. REACH data
requirements are tonnage triggered, with
no requirement for acute toxicity data for
substances produced or imported in
volumes of less than 1 metric ton per
annum (tpa). Acute toxicity data via
a single exposure route are required for
substances at volumes above 1 tpa, and
data for a second route are required for
substances at levels of 10 tpa and above.
REACH speciﬁes that in vivo testing in
vertebrates should only be considered as
a ‘‘last resort’’ and provides speciﬁc
criteria for waiving or adapting certain
in vivo data requirements, e.g., the
requirement for an oral study may be
waived if an acute inhalation study is
available or the material is corrosive.
A case for a data waiver could also be
made if testing by a particular route is not
relevant based on human exposure
scenarios, e.g., testing a gaseous substance
via the oral route.
The Toxic Substances Control Act (TSCA;
USC, 1976). No speciﬁc testing or data
requirements are imposed for new
chemicals, although companies are
required to ﬁle a pre-manufacture notice.
For existing chemicals, EPA has the
authority to require companies to submit
‘‘all existing data concerning the
environmental and health effects of
[a chemical] or mixture’’; however, this
authority is seldom used. Instead, EPA has
launched a series of voluntary programs:
Act on the Evaluation of Chemical
Substances and Regulation of Their
Manufacture, etc. Two components:
a premanufacturing evaluation of new
chemical substances and monitoring/
regulations based on the properties of
chemical substances (METI, 2005). The
hazard-based premanufacturing evaluation
is primarily concerned with a chemical’s
biopersistence and potential sub/chronic
risks to human health and the
environment. Acute toxicity studies are not
speciﬁcally listed as a premanufacturing
data requirement.
Measures for the Environmental
Administration of New Chemical
Substances (MEP, 2003); guideline for the
hazard evaluation of new chemical
substances (MEP, 2004a). Notiﬁcation and
registration provisions specify a premarket
hazard evaluation by the MEP Chemical
Registration Center, which normally
requires the submission of acute toxicity
data (MEP, 2004a). The hazard assessment
principles and test guidelines mirror those
set out by the OECD. Data requirements
may be waived on a case-by-case basis
provided a compelling scientiﬁc rationale
can be provided (MEP, 2004b). Where test
data originate from laboratories outside
China, the laboratories involved must be
Good Laboratory Practice accredited by
the competent authority of the country in
which the laboratory is located (MEP,
2003). Because China is not a party to the
OECD Mutual Acceptance of Data,
foreign data may or may not be accepted
and chemicals may be subject to duplicate
testing within China (RPA, 2004).
—High Production Volume (HPV) Chemical
Challenge Program
—Voluntary Children’s Chemical Evaluation
Program
—HPV ‘‘orphan chemicals’’ test rule (March
2006)
—Extended HPV Program
—Chemical Assessment and Management
Program (ChAMP—on hold pending
reauthorization/revision of TSCA); Each
of these programs calls for the submission
of at least Screening Information Data Set-
level data (EPA, 2007a), which in all cases
include an acute systemic toxicity study by
at least one exposure route.
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9The Globally Harmonized System of Classiﬁcation and
Labeling (GHS) was developed under the auspices of the
United Nations (UN, 2007) to promote increased consistency
among diverse national and sectoral frameworks. To date,
the GHS has been or is being implemented in the EU,
New Zealand, Korea, China, India, Japan, and the United
States (OECD, 2007a), although in certain cases, the ﬂexibility
provided by the GHS modular design has led to continued
differences in implementation. For example, European author-
ities and the U.S. Occupational Safety and Health Administra-
tion accept a limit dose of 2000 mg/kg (i.e., GHS category 4),
beyond which a substance or product is not required to bear an
acute hazard label (OJ, 2008; OSHA, 2009), whereas other
authorities require testing to a limit dose of 5000 mg/kg (i.e.,
GHS category 5) to support a no-label designation. Figures 1
and 2 illustrate the different hazard class cutoffs between the
GHS, EU, and U.S. pesticide (EPA, 2004) classiﬁcation
schemes.
The majority of European companies surveyed reported using
2000 mg/kg as the default limit dose, and the GHS itself
expressly discourages testing beyond 2000 mg/kg for animal
welfare reasons (UN, 2007). Regulatory guidance is also available
to support extrapolation of data gained with a limit dose of 2000
to GHS category 5 without retesting (OJ, 2004). However,
ongoing geopolitical differences continue to inspire duplicative
animal testing (e.g., to retain a no-label designation in a country
or sector where GHS category 5 is considered mandatory).
Scientiﬁc drivers. There have been several scientiﬁc
reasons proposed for conducting acute toxicity studies.
Potential drivers have been gathered from the 2003 pharma-
ceutical industry initiative, as well as the more recent EPAA
survey of member companies in other sectors, and appear to be
common across industrial sectors. These are listed below,
together with a discussion of their merit.
  First indication of systemic toxicity during substance
development
  Assessing hazard for workers in manufacturing/
production plants
  Selection criterion (e.g., to avoid development of highly
toxic compounds)
  Establishing dose levels for subsequent repeated dose
toxicity studies
Each of the above statements has some merit when acute
lethality studies are conducted for regulatory purposes anyway
(e.g., to support hazard classiﬁcation and labeling). However, it
is not necessary to conduct an acute toxicity study to address
these scientiﬁc objectives per se. In fact, in terms of dose
setting for a repeated dose study, the use of lethality as
a speciﬁc end point is counterintuitive. Other study types with
more reﬁned end points (e.g., a dose escalation study to
identify maximum tolerated dose) can equally address these
objectives. This also holds true in cases where repeated dose
toxicity data are available.
FIG. 1. Hazard classiﬁcation schemes for acute oral toxicity as deﬁned under the UN GHS, EU CLP, and U.S. pesticide regulations.
FIG. 2. Hazard classiﬁcation schemes for acute dermal toxicity as deﬁned under the UN GHS, EU CLP, and U.S. pesticide regulations.
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This statement assumes that the data obtained from acute
toxicity studies provide information on the likely effects of
acute overdose or accidental exposure in humans. However, the
EPAA and pharmaceutical industry surveys demonstrated that
these studies do not normally include clinical pathology,
microscopic pathology, or toxicokinetic evaluation, which
would provide useful information to aid in risk assessment. In
addition, clinical observations seen in rodents at doses above
1000 mg/kg are often nonspeciﬁc and do not add information
that would support measures to be taken in overdose or
accidental exposure situations in humans.
A pilot survey of European and U.S. poison centers
conducted by the NC3Rs and AstraZeneca indicated that 6 of
10 do not use the acute toxicity data in animals to manage cases
of overdose in humans (Robinson and Chapman, 2009). Four
centers stated that they do use animal acute toxicity data.
However, the data that these poison centers thought were
useful, such as target organ or mode of toxicity, are not
normally provided by conventional acute toxicity studies. To
explore this issue further, the NC3Rs held a workshop in
January 2010, bringing together representatives from interna-
tional poison centers, the pharmaceutical and chemical in-
dustries, and regulatory bodies to discuss whether and how
acute toxicity data are used to assess and treat cases of
pharmaceutical overdose and chemical poisoning. The dis-
cussions from this workshop are currently being written up for
publication elsewhere.
  Speciﬁc organs affected and mechanism of toxic action
The EPAA and pharmaceutical industry surveys have shown
that microscopic pathology is not routinely performed during
acute toxicity studies, which essentially negates their value in
identifying target organs or mechanisms of toxic action.
In conclusion, it is evident that the scientiﬁc drivers listed
above may have some merit when acute toxicity tests are
conducted for regulatory purposes, such as classiﬁcation and
labeling. However, in the absence of a speciﬁc regulatory
requirement, the scientiﬁc objectives can equally be met by
other study designs that do not include lethality as the end point
and that include parameters that could assist risk assessment
(e.g., histopathology, clinical pathology, and measures of
systemic exposure).
ALTERNATIVE APPROACHES
This section outlines accepted and emerging strategies with
the potential to affect an immediate and substantial reduction in
the number of animals used in regulatory acute toxicity testing
(Table 3). A more extensive listing of ongoing and historic
activities aimed at reﬁnement, reduction, and replacement of
animal use in acute toxicity studies is provided in Table 1.
Discontinuing Redundant Multiroute Testing
Retrospective data analyses have been undertaken by Creton
et al. (2010) and Seidle, Prieto, and Bulgheroni (submitted for
publication elsewhere) to ascertain the value of regulatory
requirements prescribing multiroute testing for acute systemic
toxicity. These analyses have examined the concordance
among regulatory classiﬁcations for acute oral, dermal, and/
or inhalation toxicity for ~500 agrochemical and biocidal
active substances and nearly 2000 industrial chemicals. The
ﬁndings from these two independent reviews have revealed that
acute dermal studies of pure substances do not add value above
and beyond oral data for hazard classiﬁcation of pesticides,
biocides, or chemicals. Follow-up work is currently under way
by Seidle to ascertain whether this conclusion holds true for
multicomponent formulations. Concordance between oral and
inhalation data sets was also reasonably high for certain
substance classes, suggesting that it may be possible to develop
waiver criteria for inhalation testing, subject to further review
and analysis including consideration of factors, such as
physicochemical properties, bioavailability, etc. An interna-
tional workshop to discuss the ﬁndings on redundancy of the
dermal route with industry and regulators is planned for
September 2010.
Nontesting Approaches
A range of nontesting approaches, including chemical
grouping and read across, weight of evidence, exposure-based
waiving, and various calculation methods, could be put to
immediate use to satisfy regulatory requirements for acute
toxicity data without new testing. These approaches are
commonly accepted under most regulatory frameworks in-
cluding EU and U.S. pesticide and chemical regulations and
international regulations implementing the GHS.
‘‘Chemical grouping and read across’’ is based on the
recognition that substances with similar molecular structures
often share similar toxicological proﬁles, and where end point
data are available for one member of a chemical family, these
data may be used to bridge a gap for another member of the
same chemical family. This approach requires expert judgment,
which may be augmented by ‘‘in silico’’ tools, such as the
OECD (quantitative) structure-activity-relationship ((Q)SAR)
toolbox (OECD, 2009b) or the Ambit 2.0 database (‘‘http:
//ambit.sourceforge.net’’).
‘‘Weight of evidence’’ recognizes that data exist which on
their own would not be sufﬁciently robust or reliable for
regulatory purposes but that when relevant data from different
sources (e.g., animal studies that were not performed to current
standards, in vitro data, (Q)SARs predictions, and threshold
considerations) are combined using expert judgment, sound
regulatory conclusions can be drawn. Further information on
how read-across and weight-of-evidence approaches may be
implemented can be found in ECHA (2008a) guidance
documents and elsewhere (OECD, 2007b; Worth et al., 2007).
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formulated products containing mixtures of chemicals, a num-
ber of organizations, and regulations, including the GHS,
provide guidance on the use of calculation methods to
determine the toxicity and appropriate classiﬁcation, thus
avoiding the need for acute toxicity testing (UN, 2007; WHO,
2005). Classiﬁcation can be determined on the basis on the
toxicological properties of the individual ingredients and their
relative proportions within the mixture or formulation.
Exposure-based adaptation. Where exposure can be dem-
onstrated to be negligible, or the risk of exposure is low, it could
be argued that hazard characterization, i.e., an acute toxicity
study, is unnecessary.
Estimation of Acute Oral Toxicity from 28-Day General
Toxicity Studies
In 2008, European Centre for the Validation of Alternative
Methods performed an investigation to explore whether it is
possible to identify nontoxic compounds (LD50 > 2000 mg/kg)
using information from 28-day repeated dose toxicity studies.
Taking into account the high prevalence of nontoxic substances
(87% of 4219) in the EU’s New Chemicals Database
(Bulgheroni et al., 2009), a No Observed Adverse Effect
Level threshold was set that allowed the correct identiﬁcation
of 63% of nontoxic compounds, while less than 1% of harmful
compounds were misclassiﬁed as nontoxic. The proposed
approach could permit the waiving of acute oral testing of more
than 50% of chemical substances. Although the research
focused on using the proposed approach for cosmetic
ingredients, it could potentially also be applied for chemicals
in other sectors where 28-day studies are performed.
Use of In vitro Data to Set Starting Doses
Based on an analysis showing strong concordance between
in vitro cytotoxicity data and human lethal blood concentrations,
i.e., R
2 ¼ 0.77–0.83 (Ekwall et al.,1 9 9 8 ), it was recommended
in 2000 that basal cytotoxicity tests be put to immediate use in
establishing starting doses for acute oral toxicity studies in
animals as a means of reducing animal use, e.g., by up to 40%
in relation to OECD 425 (ICCVAM/NICEATM, 2001b). The
following year, U.S. validation authorities published a guidance
document on the use of in vitro data to estimate oral starting
doses (ICCVAM/NICEATM, 2001a), although to date, this
approach does not appear to have been widely taken up in
practice. More recently, the OECD (2009a) has undertaken to
update this guidance for an international audience to promote
wider awareness and use of this animal reduction strategy.
CONCLUSIONS AND RECOMMENDATIONS
In the following, conclusions and recommendations are listed
in hierarchical order according to the authors’ perspective:
1.Before considering any acute toxicity test, it is recom-
mended that all relevant information (from historical animal
tests or other sources) on a substance or product, as well as on
similar substances or products, be thoroughly evaluated to
determine whether one or more nontesting approaches could be
used to satisfy regulatory needs.
2. Acute lethality testing is now largely historic in three
regulatory sectors (i.e., pharmaceuticals, food additives/
ﬂavorings/contact materials, and in the EU, cosmetics).
EPAA’s survey of 18 member companies revealed that the
primary driver for conducting acute toxicity studies is to meet
regulatory requirements for classiﬁcation and labeling. While
some companies cited other scientiﬁc drivers (e.g., ﬁrst
estimate of systemic toxicity, dose selection for other animal
studies, or target organ identiﬁcation), this information can be
obtained from studies that do not use lethality as an end point.
There would therefore appear to be little or no scientiﬁc basis
for the continued use of death as an end point. It is
recommended that regulators and policy makers worldwide
critically examine whether conventional approaches to acute
toxicity testing could not be replaced by nonlethal approaches
for making classiﬁcation and labeling determinations.
3. Recent studies have demonstrated that there is little or no
value in performing an acute dermal study where oral data are
already available and that a signiﬁcant opportunity exists to
reduce animal for this purpose. It is recommended at
a minimum that requirements for acute dermal testing of
chemicals and pesticide and biocide active substances be
deleted from relevant legislation, regulations, and implement-
ing guidance. Similar steps should also be considered for
mixtures and formulations, except perhaps where a penetration
enhancer is present.
4. While the majority of European companies reported using
a limit dose of 2000 mg/kg in oral and dermal studies, a small
number reported testing up to 5000 mg/kg to meet regulatory
requirements elsewhere in the world. Meanwhile, in the
pharmaceutical sector, the standard limit dose has been reduced
to 1000 mg/kg. The ultimate goal of acute toxicity testing, i.e.,
to provide information on potential hazards and reduce the risk
of accidental poisoning, was the same for all sectors, and it is
therefore questionable whether a need exists for different limit
doses. OECD guidelines and the GHS state that testing above
2000 mg/kg is discouraged for reasons of animal welfare and
should only be considered when there is a strong likelihood
that results would have a direct relevance for protecting health
or the environment. With this in mind, and given that EPAA’s
survey suggests acute toxicity testing is rarely used for
scientiﬁc purposes including risk assessment, it is recommen-
ded that the limit dose of 5000 mg/kg be reduced to at most
2000 mg/kg or preferably 1000 mg/kg. This should be
considered in cases where no data on acute toxicity are yet
available and not lead to retesting.
5. Within the pharmaceutical sector, the recent revision of
the ICH M3 guideline to remove the requirement for acute
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represents a signiﬁcant advance in reducing animal use for
this purpose. To ensure full implementation of this change, it
is recommended that regional regulatory requirements and
guidance (i.e., EMEA, 1987; FDA, 1996) be revised and
brought into line with current ICH guidelines as a matter of
priority.
6. Our review highlighted the existence of substantially
discordant regulatory policies and testing requirements in
certain emerging markets (e.g., mandatory ﬁnished product
testing, the requirement to carry out some tests within the
country to which a product is to be exported, and failure
to routinely accept foreign-generated data). It is recom-
mended that regulatory authorities worldwide strive to
enhance international harmonization of data requirements
in affected sectors and to ensure mutual recognition of test
results among authorities in both existing and emerging
markets.
7. An historical data review has demonstrated that 28-day
repeated dose toxicity studies can be used to identify
compounds that are not acutely toxic (LD50 > 2000 mg/kg),
which suggests that in vivo testing could be avoided for these
substances, thereby substantially reducing animal use in acute
toxicity testing. It is recommended that opportunities to
implement this approach in practice be explored, e.g., under
REACH and other chemical assessment programs where the
28-day study is legally required.
8. Where acute toxicity testing cannot be avoided, it is
recommended that account be taken of the study objective (i.e.,
point estimation or simple classiﬁcation), as well as the reasonably
expected LD50 or LC50, when choosing the protocol in order that
the fewest animals will be used in achieving the objective.
As this paper highlights, the regulatory landscape across
industry sectors and geographical regions is complex, and
multiple efforts are ongoing to promote the 3Rs in acute
toxicity testing across sectors and parts of the globe. However,
there remains a need for greater cross-sector and international
cooperation to ensure that developments that can reduce, reﬁne,
and ultimately replace the use of animals in acute toxicity
testing, while assuring safety, are fully implemented.
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